Table 2. Summary of meta-analysis finding.
Overall/subgroup/sensitivity analysesa | No. of patients (trials) | Effect sizes [95% CI] | Quality of the evidence GRADE |
---|---|---|---|
Telephone-based interventions (with educational materials) vs. usual care | |||
Pain (primary outcome) | |||
Overall analysis | 1,357 (5 trials) | −0.27 [−0.53, −0.01]b | ⊕⊕⊕⊖ Moderatec |
Patient condition | |||
Osteoarthritis | 1,212 (3 trials) | −0.16 [−0.47, 0.14] | |
Spinal pain | 145 (2 trials) | −0.55 [−0.92, −0.19]b | |
Sensitivity analyses | |||
Excluding small trials | 1,212 (3 trials) | −0.16 [−0.47, 0.14] | |
Disability (primary outcome) | |||
Overall analysis | 1,537 (7 trials) | −0.21 [−0.40, −0.02]b | ⊕⊕⊕⊖ Moderatec |
Patient condition | |||
Osteoarthritis | 1,417 (5 trials) | −0.13 [−0.30, 0.04] | |
Spinal pain | 120 (2 trials) | −0.64 [−1.01, −0.27]b | |
Subgroup analyses | |||
Intervention type | |||
Single component | 201 (2 trials) | −0.30 [−0.59, −0.01]b | |
Multicomponent | 1,492 (5 trials) | −0.18 [−0.42, 0.06] | |
Sensitivity analyses | |||
Excluding small trials | 1,212 (3 trials) | −0.10 [−0.34, 0.14] | |
Psychological symptoms (secondary outcome) | |||
Overall analysis | 1,293 (5 trials) | 0.03 [−0.10, 0.16] | ⊕⊕⊕⊖ Moderated |
Patient condition | |||
Osteoarthritis | 1,242 (4 trials) | 0.03 [−0.13, 0.19] | |
Sensitivity analyses | |||
Excluding small trials | 1,212 (3 trials) | 0.02 [−0.16, 0.20] | |
Self-efficacy (secondary outcome) | |||
Overall analysis | 571 (3 trials) | 0.20 [0.03, 0.38]b | ⊕⊕⊕⊕ High |
Patient condition | |||
Osteoarthritis | 545 (2 trials) | 0.19 [0.01, 0.36]b | |
Subgroup analysis | |||
Intervention type | |||
Multicomponent | 545 (2 trials) | 0.19 [0.01, 0.36]b | |
Weight loss (secondary outcome) | |||
Overall analysis | 697 (2 trials) | −0.07 [−0.25, 0.11] | ⊕⊕⊕⊖ Moderated |
Telephone plus face-to-face interventions vs. usual care | |||
Pain (primary outcome) | |||
Overall analysis | 259 (3 trials) | −0.08 [−0.32, 0.16] | ⊕⊕⊕⊖ Moderated |
Patient condition | |||
Spinal pain | 225 (2 trials) | −0.09 [−0.36, 0.17] | |
Disability (primary outcome) | |||
Overall analysis | 398 (4 trials) | −0.08 [−0.28, 0.12] | ⊕⊕⊕⊖ Moderated |
Patient condition | |||
Spinal pain | 364 (3 trials) | −0.11 [−0.31, 0.10] | |
Subgroup analyses | |||
Spinal pain duration (chronic) | 225 (2 trials) | 0.00 [−0.26, 0.26] | |
Psychological symptoms (secondary outcome) | |||
Overall analysis | 298 (2 trials) | −0.12 [−0.35, 0.11] | ⊕⊕⊕⊖ Moderated |
Telephone plus comprehensive face-to-face interventions vs. face-to-face interventions alone | |||
Pain (primary outcome) | |||
Overall analysise | 513 (3 trials) | −0.13 [−0.30, 0.04] | ⊕⊕⊕⊖ Moderated |
Disability (primary outcome) | |||
Overall analysise | 513 (3 trials) | −0.06 [−0.31, 0.19] | ⊕⊕⊕⊖ Moderated |
Psychological symptoms (secondary outcome) | |||
Overall analysise | 345 (2 trials) | 0.11 [−0.10, 0.32] | ⊕⊕⊕⊖ Moderated |
Notes:
Planned subgroup and sensitivity analyses were not conducted due to insufficient study numbers: telephone-based interventions (with educational materials) vs. usual care (n = 38); patient condition (spinal pain (n = 3)), by intervention type (single (n = 4) and multicomponent (n = 4)), by modality (telephone (n = 5) and videoconferencing (n = 5)), by condition duration (acute (n = 5) and chronic (n = 5)), by high risk of bias (n = 5), and by trial size (n = 2). Telephone plus face-to-face interventions vs. usual care (n = 28): patient condition (osteoarthritis (n = 3), spinal pain (n = 1)), by intervention type (single (n = 3) and multicomponent (n = 3)), by modality (telephone (n = 3) and videoconferencing (n = 3)), by condition duration (acute (n = 3) and chronic (n = 2)), by high risk of bias (n = 4), and by trial size (n = 3). Telephone plus comprehensive face-to-face interventions vs. face-to-face interventions alone (n = 24); by patient condition (osteoarthritis (n = 3), spinal pain (n = 3)), by intervention type (singular (n = 3) and multicomponent (n = 3)), by modality (telephone (n = 3) and videoconferencing (n = 3)), by high risk of bias (n = 3) and by trial size (n = 3).
Significant at p < 0.05.
Downgraded due to inconsistency of results: I2 > 50%.
Downgraded due to imprecision: the confidence intervals contained the null value.
One study (De Rezende et al., 2016) which compared two interventions entered into RevMan.